(SNDX) Syndax Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.776m USD | Total Return: 84.5% in 12m

Menin Inhibitors, Monoclonal Antibodies, HDAC Inhibitors, Oncology Drugs
Total Rating 32
Safety 22
Buy Signal -0.37
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.78B
Avg Turnover: 33.6M
Risk 3d forecast
Volatility54.4%
VaR 5th Pctl8.92%
VaR vs Median-0.47%
Reward TTM
Sharpe Ratio1.28
Rel. Str. IBD71.5
Rel. Str. Peer Group44.8
Character TTM
Beta0.737
Beta Downside1.045
Hurst Exponent0.472
Drawdowns 3y
Max DD64.81%
CAGR/Max DD-0.01
CAGR/Mean DD-0.04
EPS (Earnings per Share) EPS (Earnings per Share) of SNDX over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.44, "2021-09": -0.4, "2021-12": 1.81, "2022-03": -0.63, "2022-06": -0.62, "2022-09": -0.58, "2022-12": -0.62, "2023-03": -0.59, "2023-06": -0.64, "2023-09": -0.73, "2023-12": -1, "2024-03": -0.85, "2024-06": -0.8, "2024-09": -0.98, "2024-12": -1.1, "2025-03": -0.9846, "2025-06": -0.83, "2025-09": -0.7, "2025-12": -0.78, "2026-03": -0.48,
Last SUE: 0.32
Qual. Beats: 0
Revenue Revenue of SNDX over the last years for every Quarter: 2021-03: 0.379, 2021-06: 0.379, 2021-09: 12.375, 2021-12: 126.576, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.536, 2024-03: 0, 2024-06: 3.5, 2024-09: 12.5, 2024-12: 7.68, 2025-03: 20.042, 2025-06: 37.958, 2025-09: 45.871, 2025-12: 68.481, 2026-03: 64.864,
Last SUE: -0.17
Qual. Beats: 0

Warnings

Interest Coverage Ratio -2.8 is critical

Beneish M-Score -1.23 > -1.5 - likely earnings manipulation

Altman Z'' -11.81 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: SNDX Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc. (SNDX) is a New York-based biotechnology firm focused on oncology and targeted therapies. Its primary pipeline features Revuforj (revumenib), a menin inhibitor targeting acute leukemias, and Niktimvo (axatilimab), an antibody designed for chronic graft-versus-host disease (cGVHD). The company also maintains a licensing partnership with Eddingpharm for the development of Entinostat, a Class 1 HDAC inhibitor.

The company operates within the biotechnology sector, which typically requires high research and development expenditure and relies on the successful navigation of multi-phase clinical trials for regulatory approval. This business model often involves strategic collaborations to manage the capital-intensive process of global commercialization.

Investors can further examine the company’s pipeline progression and financial health by visiting ValueRay. Syndax continues to expand its clinical scope by testing its lead candidates in combination with standard-of-care agents for various mutations of acute myeloid leukemia and solid tumors.

Headlines to Watch Out For
  • FDA approval and commercial launch of Revuforj drive near-term revenue growth
  • Market uptake of Niktimvo for graft-versus-host disease determines long-term profitability
  • Clinical trial results for revumenib in mNPM1 AML impact valuation expansion
  • High research and development expenses increase cash burn and capital requirements
  • Strategic partnerships and licensing agreements influence future pipeline development funding
Piotroski VR-10 (Strict) 0.5
Net Income: -243.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.41 > 0.02 and ΔFCF/TA 3.61 > 1.0
NWC/Revenue: 177.3% < 20% (prev 1.04k%; Δ -861.6% < -1%)
CFO/TA -0.59 > 3% & CFO -278.2m > Net Income -243.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.47 > 1.5 & < 3
Outstanding Shares: last quarter (86.6m) vs 12m ago 1.17% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 39.01% > 50% (prev 6.82%; Δ 32.19% > 0%)
Interest Coverage Ratio: -2.77 > 6 (EBITDA TTM -223.5m / Interest Expense TTM 80.7m)
Altman Z'' -11.81
A: 0.81 (Total Current Assets 471.2m - Total Current Liabilities 86.2m) / Total Assets 472.7m
B: -3.28 (Retained Earnings -1.55b / Total Assets 472.7m)
C: -0.40 (EBIT TTM -223.5m / Avg Total Assets 556.7m)
D: -3.59 (Book Value of Equity -1.55b / Total Liabilities 431.0m)
Altman-Z'' = -11.81 = D
Beneish M -1.23
DSRI: 0.36 (Receivables 38.1m/21.5m, Revenue 217.2m/43.7m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.00 (AQ_t 0.00 / AQ_t-1 0.14)
SGI: 4.97 (Revenue 217.2m / 43.7m)
TATA: 0.07 (NI -243.2m - CFO -278.2m) / TA 472.7m)
Beneish M = -1.23 (Cap -4..+1) = D
What is the price of SNDX shares?

As of May 24, 2026, the stock is trading at USD 19.77 with a total of 1,204,009 shares traded.
Over the past week, the price has changed by -1.43%, over one month by -9.69%, over three months by +0.20% and over the past year by +84.46%.

Is SNDX a buy, sell or hold?

Syndax Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SNDX.

  • StrongBuy: 9
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the SNDX price?
Analysts Target Price 39.3 98.5%
Syndax Pharmaceuticals (SNDX) - Fundamental Data Overview as of 22 May 2026
P/S = 8.1888
P/B = 42.8552
Revenue TTM = 217.2m USD
EBIT TTM = -223.5m USD
EBITDA TTM = -223.5m USD
Long Term Debt = 344.0m USD (from longTermDebt, last quarter)
Short Term Debt = 488k USD (from shortTermDebt, last quarter)
Debt = 346.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.40m
Net Debt = -5.31m USD (calculated: Debt 346.8m - CCE 352.1m)
Enterprise Value = 1.77b USD (1.78b + Debt 346.8m - CCE 352.1m)
Interest Coverage Ratio = -2.77 (Ebit TTM -223.5m / Interest Expense TTM 80.7m)
EV/FCF = -9.11x (Enterprise Value 1.77b / FCF TTM -194.4m)
FCF Yield = -10.98% (FCF TTM -194.4m / Enterprise Value 1.77b)
FCF Margin = -89.50% (FCF TTM -194.4m / Revenue TTM 217.2m)
Net Margin = -112.0% (Net Income TTM -243.2m / Revenue TTM 217.2m)
 Gross Margin = unknown ((Revenue TTM 217.2m - Cost of Revenue TTM 4.44m) / Revenue TTM)
 Tobins Q-Ratio = 3.75 (Enterprise Value 1.77b / Total Assets 472.7m)
Interest Expense / Debt = 23.27% (Interest Expense 80.7m / Debt 346.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -176.6m (EBIT -223.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.86 (Total Current Assets 471.2m / Total Current Liabilities 97.0m)
Debt / Equity = 8.33 (Debt 346.8m / totalStockholderEquity, last quarter 41.6m)
 Debt / EBITDA = 0.02 (negative EBITDA) (Net Debt -5.31m / EBITDA -223.5m)
 Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -5.31m / FCF TTM -194.4m)
 Total Stockholder Equity = 94.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.70% (Net Income -243.2m / Total Assets 472.7m)
RoE = -14.80% (Net Income TTM -243.2m / Total Stockholder Equity 1.64b)
RoCE = -11.24% (EBIT -223.5m / Capital Employed (Equity 1.64b + L.T.Debt 344.0m))
 RoIC = -170.7% (out of range, set to none) (NOPAT -176.6m / Invested Capital 103.4m)
 WACC = 10.18% (E(1.78b)/V(2.12b) * Re(8.58%) + D(346.8m)/V(2.12b) * Rd(23.27%) * (1-Tc(0.21)))
Discount Rate = 8.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.01 | Cagr: 8.22%
 [DCF] Fair Price = unknown (Cash Flow -194.4m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.17 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=+6.40% | Revisions=+17% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.39 | Chg30d=+0.28% | Revisions=-27% | Analysts=11
EPS current Year (2026-12-31): EPS=-1.68 | Chg30d=+2.78% | Revisions=-29% | GrowthEPS=+49.1% | GrowthRev=+100.9%
EPS next Year (2027-12-31): EPS=-0.21 | Chg30d=+25.91% | Revisions=-17% | GrowthEPS=+87.6% | GrowthRev=+56.1%
[Analyst] Revisions Ratio: -29%